Medical Access and Reimbursement in United Kingdom

Psilocybin and psilocin-containing fungi are listed as Class A and Schedule 1 controlled drugs in the UK. No psilocybin medicine was identified as MHRA-authorised or routinely NHS-reimbursed in this refresh. Access should be treated as limited to properly authorised research unless a specific institution can document both a legal route and a funding route. # # # #

MDMA is treated as a Class A and Schedule 1 controlled drug in UK materials. The current public medical-access signal is clinical research, such as the King's veteran PTSD feasibility study, not routine prescribing or NHS reimbursement. No licensed MDMA medicine or UK-wide reimbursement pathway was identified in the sources reviewed. # # # # #

Spravato is a licensed medicine in the UK for treatment-resistant major depressive disorder and for acute short-term treatment of depressive symptoms in psychiatric emergency settings, under psychiatrist supervision and clinical monitoring. Licensing does not mean uniform NHS access. NICE does not recommend esketamine with an SSRI or SNRI for treatment-resistant depression in England and Wales, and NICE terminated the separate imminent-suicide-risk appraisal because the company did not provide an evidence submission. # # #

Scotland differs from England and Wales: the Scottish Medicines Consortium accepted esketamine for treatment-resistant major depression, subject to an approved NHSScotland patient access scheme. Northern Ireland lists TA854 as endorsed, which means the negative NICE appraisal is recognised there rather than replaced by a separate positive recommendation. Local operational access should still be checked before making patient-facing claims. # # #

Ketamine is Class B and Schedule 2 in UK controlled-drug materials and remains a legitimate medical anaesthetic. Its psychiatric use for depression is different: Oxford Health states that ketamine for depression is off-label, and its public service information describes a mainly self-pay model with limited NHS-funded access for certain Oxfordshire or Buckinghamshire patients referred internally by an Oxford Health consultant psychiatrist. # # #

Other specialist signals exist, including Northamptonshire Healthcare's Centre for Neuromodulation and research such as the EDEN ketamine study. These examples support a limited, specialist and local access picture, not a nationally standardised NHS reimbursement route for antidepressant ketamine. # # #

DMT is listed as a Class A and Schedule 1 controlled drug. The UK has visible DMT research, including the SPL026 depression paper and UCL's DMT and drinking study, but no authorised DMT medicine or routine reimbursement pathway was identified. Public access claims should therefore be framed as research-only unless a future MHRA or HTA decision changes that position. # # # # #

5-MeO-DMT is listed as Class A and Schedule 1. Beckley Psytech's BPL-003 programme gives the UK a strong research and development signal, but the public evidence reviewed here does not establish MHRA authorisation or NHS reimbursement. Access should be described as clinical research only. # # # #

No authorised ibogaine medicine, NICE or SMC reimbursement route, or current EAMS pathway was identified in this refresh. Any medical-access claim would need product-specific evidence from MHRA, a named institution and a funding route. In practical public-country-page language, ibogaine should not be presented as available for routine UK care. # #

Ayahuasca is not an authorised UK medicine. Preparations containing DMT or other controlled tryptamines should be treated as falling within controlled-drug risk, because DMT is Class A and Schedule 1. No routine NHS reimbursement, licensed product or UK-wide medical pathway was identified. # # #

Mescaline is listed as Class A and Schedule 1 in UK controlled-drug materials. No authorised mescaline medicine or routine NHS reimbursement pathway was identified. Any lawful medical work would require the relevant research and controlled-drug permissions. # # #

Representative 2C-series compounds are covered by Class A controls in the UK controlled-drug list. No authorised medical product, NHS reimbursement route or active public medical access pathway was identified for this compound family in the sources reviewed. # #